Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03872947 · ClinicalTrials.gov registry record · Phase 1

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

A Phase 1 study of Colorectal Cancer and Ovarian Cancer, sponsored by Toray Industries.

Active
Registry status
Phase 1
Development phase
138
Enrollment target
14
Study locations

NCT03872947 is a Phase 1 study of Colorectal Cancer and Ovarian Cancer that is active but no longer recruiting, run by Toray Industries. The registered enrollment target is 138 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 14 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03872947, a Phase 1 study of Colorectal Cancer and Ovarian Cancer, is active but no longer recruiting, sponsored by Toray Industries.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
138 participants
Enrollment target
14
Study locations

Study Summary

The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.

Conditions Studied

Colorectal Cancer Ovarian Cancer Melanoma Solid Tumor Bladder Cancer Gastric Cancer Renal Cell Carcinoma Cholangiocarcinoma Epithelial Ovarian Cancer Palpable Subcutaneous Malignant Lesions

Interventions

  • DRUG Leucovorin
  • DRUG Irinotecan
  • BIOLOGICAL TRK-950

Study Locations (14)

Arizona

  • HonorHealth Research Institute - Scottsdale
  • AOA-HOPE - Tucson

California

  • USC Norris Comprehensive Cancer Center - Los Angeles
  • HOAG Memorial Hospital Presbyterian - Newport

Oregon

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute and Research Center) - Eugene
  • Northwest Cancer Specialists - Portland

Texas

  • Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center - Dallas
  • Texas Oncology - Downtown Fort Worth Cancer Center - Fort Worth

Louisiana

  • Ochsner Clinic Foundation - New Orleans

New Jersey

  • Atlantic Health System - Morristown

New York

  • Perlmutter Cancer Center at NYU Langone - New York

Virginia

  • Virginia Cancer Specialists, PC - Leesburg

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2019-04-26
Est. Completion 2026-06
Phase Phase 1

Sponsor

Toray Industries

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03872947

The ClinicalTrials.gov registry entry for NCT03872947 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Toray Industries, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Leucovorin is the first listed.

NCT03872947 reports 14 study locations spanning 10 distinct geographic areas - top geographies include Arizona, California, Oregon.

Frequently Asked Questions

What is clinical trial NCT03872947 about?

NCT03872947 is a clinical study titled "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors". The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carbop...

What is the current status of trial NCT03872947?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2019-04-26. Estimated completion is 2026-06.

What conditions does trial NCT03872947 study?

This clinical trial studies the following conditions: Colorectal Cancer, Ovarian Cancer, Melanoma, Solid Tumor, Bladder Cancer.

What interventions are being tested in trial NCT03872947?

The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), TRK-950 (BIOLOGICAL).

Who is sponsoring clinical trial NCT03872947?

This trial is sponsored by Toray Industries, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03872947 being conducted?

This trial has 14 study locations across Arizona, California, Louisiana, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.